Clinical Trial Results:
A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and pre-term neonates and infants up to 3 months of age with late-onset sepsis
Summary
|
|
EudraCT number |
2022-001837-35 |
Trial protocol |
LT LV SK PL Outside EU/EEA EE BG DE |
Global end of trial date |
18 Dec 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jul 2025
|
First version publication date |
02 Jul 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
BPR-PIP-003
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05856227 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
IND Number: 64.407 | ||
Sponsors
|
|||
Sponsor organisation name |
Basilea Pharmaceutica International Ltd, Allschwil
|
||
Sponsor organisation address |
Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
|
||
Public contact |
Study director, Basilea Pharmaceutica International Ltd, Allschwil, +41 616061111, medical.information@basilea.com
|
||
Scientific contact |
Study director, Basilea Pharmaceutica International Ltd, Allschwil, +41 616061111, medical.information@basilea.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000205-PIP02-11 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
28 Feb 2025
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
18 Dec 2024
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Dec 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To characterise the safety profile of ceftobiprole in term and pre-term neonates and infants
up to 3 months of age with LOS.
|
||
Protection of trial subjects |
The study was conducted according to the ethical principles that have their origins in the World Medical Association Declaration of Helsinki, the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP), and applicable national and local laws and regulations for the conduct of clinical research and the protection of personal data. If conflicts between local laws and regulations arose, more stringent requirements were adopted.
|
||
Background therapy |
The investigational medicinal product, ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment. | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
06 Aug 2023
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 1
|
||
Country: Number of subjects enrolled |
Bulgaria: 3
|
||
Country: Number of subjects enrolled |
Estonia: 2
|
||
Country: Number of subjects enrolled |
Lithuania: 1
|
||
Country: Number of subjects enrolled |
United States: 2
|
||
Worldwide total number of subjects |
9
|
||
EEA total number of subjects |
7
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
6
|
||
Newborns (0-27 days) |
2
|
||
Infants and toddlers (28 days-23 months) |
1
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
Recruitment began in August 2023. The study included pediatric patients from Europe and the USA. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 11 patients were screened for enrollment in this study, two of whom failed the screening process. Nine patients (six pre-term neonates and three term neonates) were enrolled and assigned to the study treatment. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall Trial (ITT/Safety population) (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Blinding implementation details |
Not applicable
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Pre-term Neonates | |||||||||||||||||||||
Arm description |
Pediatric patients (gestational age ≥ 24 to 36 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 7.5 mg/kg or 10 mg/kg (bodyweight < 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Ceftobiprole medocaril
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Powder for concentrate for solution for injection/infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
Study treatment consisted of IV ceftobiprole medocaril for 3 – 10 days, which could be extended to 14 days if considered clinically necessary by the Investigator. Ceftobiprole was administered as a 2-hour IV infusion, with the dose adjusted according to gestational and post-natal ages. To limit infusion volume for the pre-term and term neonates, the ceftobiprole medocaril infusion was administered at a concentration of 4 mg/mL.
|
|||||||||||||||||||||
Arm title
|
Term Neonates | |||||||||||||||||||||
Arm description |
Pediatric patients (gestational age ≥ 37 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 10 mg/kg (bodyweight < 4 kg) or 15mg/kg (bodyweight ≥ 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Ceftobiprole medocaril
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Powder for concentrate for solution for injection/infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
Study treatment consisted of IV ceftobiprole medocaril for 3 – 10 days, which could be extended to 14 days if considered clinically necessary by the Investigator. Ceftobiprole was administered as a 2-hour IV infusion, with the dose adjusted according to gestational and post-natal ages. To limit infusion volume for the pre-term and term neonates, the ceftobiprole medocaril infusion was administered at a concentration of 4 mg/mL.
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Pre-term Neonates
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Pediatric patients (gestational age ≥ 24 to 36 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 7.5 mg/kg or 10 mg/kg (bodyweight < 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Term Neonates
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Pediatric patients (gestational age ≥ 37 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 10 mg/kg (bodyweight < 4 kg) or 15mg/kg (bodyweight ≥ 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Pre-term Neonates
|
||
Reporting group description |
Pediatric patients (gestational age ≥ 24 to 36 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 7.5 mg/kg or 10 mg/kg (bodyweight < 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment. | ||
Reporting group title |
Term Neonates
|
||
Reporting group description |
Pediatric patients (gestational age ≥ 37 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months. Patients were treated with ceftobiprole 10 mg/kg (bodyweight < 4 kg) or 15mg/kg (bodyweight ≥ 4 kg) infused over 2 hours and administered every 12 hours. Ceftobiprole may have been combined with locally-provided ampicillin and/or an aminoglycoside based on the Investigator’s judgment |
|
|||||||||||||||||||||||||||||||
End point title |
Number of Patients With Adverse Events (AEs) [1] | ||||||||||||||||||||||||||||||
End point description |
Number of patients with AEs, serious adverse events (SAEs), AEs leading to discontinuations and AEs of special interest
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
Up to 5–7 weeks
|
||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As the endpoint is descriptive in nature, no statistical analysis is provided. |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Maximum Observed Plasma Concentration (Cmax) of Ceftobiprole, Ceftobiprole Medocaril, and Open-ring Metabolite | |||||||||||||||||||||
End point description |
Observed pharmacokinetic parameter Cmax of ceftobiprole (the active moiety), its pro-drug ceftobiprole medocaril and the open-ring metabolite in term and pre-term neonates with post-natal age up to 3 months
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
On treatment Day 3 prior to and 2, 4, and 8 hours after the start of the first ceftobiprole infusion of the day.
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Participants With Improved Signs and Symptoms of Late Onset Sepsis (LOS) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Improved signs and symptoms of LOS (including fever, hypothermia, abnormal heart rate, signs of impaired circulation, petechial rash or sclerema neonatorum, respiratory distress, gastrointestinal distress, irritability, lethargy and/or muscular or arterial hypotonia) assessed at Day 3, EOT, and TOC visits (ITT) populations.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At the Day 3 and up to 5-7 weeks
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Number of Patients With a Clinical Response | ||||||||||||||||||||||||||||||
End point description |
Clinical cure rate at the end of treatment (EOT) at day 3-14 and test of cure (TOC) at 7–14 days after last ceftobiprole dose visits in the Intent-to-Treat (ITT) population
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
5-7 weeks
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Number of Patients With a Microbiological Response | ||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication or presumed eradication rate at the EOT and TOC visits.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
5-7 weeks
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From first administration of study medication up to LFU visit.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Treatment-emergent adverse events and serious adverse events
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Term Neonates
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Term neonates | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Pre-term neonates
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Pre-term neonates | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
09 Jul 2024 |
The number of term and pre-term neonates was reduced from at least 15 to at least 8 patients, comprising at least two term neonates, and at least six pre-term neonates less than < 37 weeks gestational age.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |